Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

J Thorac Oncol. 2018 Nov;13(11):e232-e234. doi: 10.1016/j.jtho.2018.07.012.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides / pharmacology
  • Acrylamides / therapeutic use*
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged
  • Aniline Compounds / pharmacology
  • Aniline Compounds / therapeutic use*
  • Crizotinib / pharmacology
  • Crizotinib / therapeutic use*
  • Erlotinib Hydrochloride / pharmacology
  • Erlotinib Hydrochloride / therapeutic use*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Middle Aged
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • osimertinib
  • Crizotinib
  • Erlotinib Hydrochloride